Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037

PURPOSE: Tumours frequently have defects in multiple oncogenic pathways, e.g. MAPK and PI3K signalling pathways, and combinations of targeted therapies may be required for optimal activity. This study evaluated the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037, as single agents and...

Descripción completa

Detalles Bibliográficos
Autores principales: Haagensen, Emma J., Thomas, Huw D., Schmalix, Wolfgang A., Payne, Andrew C., Kevorkian, Lara, Allen, Rodger A., Bevan, Paul, Maxwell, Ross J., Newell, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114336/
https://www.ncbi.nlm.nih.gov/pubmed/27837257
http://dx.doi.org/10.1007/s00280-016-3186-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114336/
https://www.ncbi.nlm.nih.gov/pubmed/27837257
http://dx.doi.org/10.1007/s00280-016-3186-4

Ejemplares similares